Physician profile
David L Johnson
NPI 1770639619
$657.35
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $36.54 · 2022: $24.45 · 2023: $116 · 2024: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $227.91 | 2019 | |
| Novo Nordisk INC | $71.21 | 2020-2024 | Saxenda, Wegovy, Ozempic |
| Lilly USA, LLC | $54.84 | 2024 | Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $54.63 | 2023-2024 | Bexsero, Arexvy, Shingrix |
| Cequr Corporation | $43.20 | 2024 | Cequr Simplicity |
| Pfizer INC. | $40.64 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $37.42 | 2023-2024 | Gvoke Hypopen |
| Treace Medical Concepts, INC. | $24.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.91 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $20.75 | 2024 | Rexulti, Abilify Maintena |
| Dexcom, INC. | $18.36 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $18.32 | 2024 | Repatha, Otezla |
| Abbvie INC. | $13.18 | 2023 | |
| Agios Pharmaceuticals, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.